Clinical Impact of Revised Ciprofloxacin Breakpoint in Patients with Urinary Tract Infections by Enterobacteriaceae

In 2018, the Clinical and Laboratory Standards Institute (CLSI) revised ciprofloxacin (CIP)-susceptible breakpoint for Enterobacteriaceae from ≤1 μg/mL to ≤0.25 μg/mL, based on pharmacokinetic-pharmacodynamic (PK-PD) analysis. However, clinical data supporting the lowered CIP breakpoint are insuffic...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Antibiotics (Basel)
Hlavní autoři: Park, Ga Eun, Ko, Jae-Hoon, Cho, Sun Young, Huh, Hee Jae, Baek, Jin Yang, Ko, Kwan Soo, Kang, Cheol-In, Chung, Doo Ryeon, Peck, Kyong Ran
Médium: Artigo
Jazyk:Inglês
Vydáno: MDPI 2021
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8074352/
https://ncbi.nlm.nih.gov/pubmed/33924153
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/antibiotics10040469
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky